Literature DB >> 21125664

Signalling networks associated with urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in breast cancer tissues: new insights from protein microarray analysis.

Claudia Wolff1, Katharina Malinowsky, Daniela Berg, Kerstin Schragner, Tibor Schuster, Axel Walch, Holger Bronger, Heinz Höfler, Karl-Friedrich Becker.   

Abstract

The urokinase-type plasminogen activator (uPA) and the main uPA inhibitor PAI-1 play important roles in cell migration and invasion in both physiological and pathological contexts. Both factors are clinically applicable predictive markers in node-negative breast cancer patients that are used to stratify patients for adjuvant chemotherapy. In addition to their classical functions in plasmin regulation, both factors are key components in cancer-related cell signalling. Such signalling cascades are well described in cell culture systems, but a better understanding of uPA- and PAI-1-associated signalling networks in clinical tissues is needed. We examined the expression of uPA, PAI-1, and 21 signalling molecules in 201 primary breast cancer tissues using protein microarrays. Expression of uPA was significantly correlated with the expression of ERK and Stat3, while expression of PAI-1 was correlated with the uPA receptor and Akt activation, presumably via integrin and HER-receptor signalling. Analysis of uPA expression did not reveal any significant correlation with staging, grading or age of the patients. The PAI-1 expression was correlated with nodal stage. Network monitoring for uPA and PAI-1 in breast cancer reveals interactions with main signalling cascades and extends the findings from cell culture experiments. Our results reveal possible mechanisms underlying cancer development.
Copyright © 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21125664     DOI: 10.1002/path.2791

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  24 in total

1.  Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.

Authors:  Marko Buta; Radan Džodić; Igor Đurišić; Ivan Marković; Tijana Vujasinović; Milan Markićević; Dragica Nikolić-Vukosavljević
Journal:  Tumour Biol       Date:  2015-05-21

2.  Transforming growth factor-beta signaling leads to uPA/PAI-1 activation and metastasis: a study on human breast cancer tissues.

Authors:  D S Lang; S Marwitz; U Heilenkötter; W Schumm; O Behrens; R Simon; M Reck; E Vollmer; T Goldmann
Journal:  Pathol Oncol Res       Date:  2014-03-09       Impact factor: 3.201

3.  Evaluation of Protein Profiles From Treated Xenograft Tumor Models Identifies an Antibody Panel for Formalin-fixed and Paraffin-embedded (FFPE) Tissue Analysis by Reverse Phase Protein Arrays (RPPA).

Authors:  Sabine Bader; Magdalena Zajac; Thomas Friess; Elisabeth Ruge; Natascha Rieder; Berthold Gierke; Yvonne Heubach; Marlene Thomas; Michael Pawlak
Journal:  Mol Cell Proteomics       Date:  2015-06-23       Impact factor: 5.911

4.  Melatonin Represses Metastasis in Her2-Postive Human Breast Cancer Cells by Suppressing RSK2 Expression.

Authors:  Lulu Mao; Whitney Summers; Shulin Xiang; Lin Yuan; Robert T Dauchy; Amberly Reynolds; Melissa A Wren-Dail; David Pointer; Tripp Frasch; David E Blask; Steven M Hill
Journal:  Mol Cancer Res       Date:  2016-08-17       Impact factor: 5.852

5.  Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance.

Authors:  Sarah A Andres; Angelena B Edwards; James L Wittliff
Journal:  J Clin Lab Anal       Date:  2012-02       Impact factor: 2.352

6.  uPA and PAI-1-Related Signaling Pathways Differ between Primary Breast Cancers and Lymph Node Metastases.

Authors:  Katharina Malinowsky; Claudia Wolff; Daniela Berg; Tibor Schuster; Axel Walch; Holger Bronger; Heiko Mannsperger; Christian Schmidt; Ulrike Korf; Heinz Höfler; Karl-Friedrich Becker
Journal:  Transl Oncol       Date:  2012-04-01       Impact factor: 4.243

Review 7.  Histopathological markers of treatment response and recurrence risk in ovarian cancers and borderline tumors.

Authors:  S Avril
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

8.  Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping.

Authors:  Julia D Wulfkuhle; Daniela Berg; Claudia Wolff; Rupert Langer; Kai Tran; Julie Illi; Virginia Espina; Mariaelena Pierobon; Jianghong Deng; Angela DeMichele; Axel Walch; Holger Bronger; Ingrid Becker; Christine Waldhör; Heinz Höfler; Laura Esserman; Lance A Liotta; Karl-Friedrich Becker; Emanuel F Petricoin
Journal:  Clin Cancer Res       Date:  2012-10-08       Impact factor: 12.531

9.  Altered expression of telomere-associated genes in leukocytes among BRCA1 and BRCA2 carriers.

Authors:  Hiromi Tanaka; Elizabeth A Phipps; Ting Wei; Xi Wu; Chirayu Goswami; Yunlong Liu; George W Sledge; Lida Mina; Brittney-Shea Herbert
Journal:  Mol Carcinog       Date:  2018-01-05       Impact factor: 4.784

10.  mRNA expression in papillary and anaplastic thyroid carcinoma: molecular anatomy of a killing switch.

Authors:  Aline Hébrant; Geneviève Dom; Michael Dewaele; Guy Andry; Christophe Trésallet; Emmanuelle Leteurtre; Jacques E Dumont; Carine Maenhaut
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.